C
CMAB BioPharm
Biopharmaceutical Service Firm
About CMAB BioPharm
Established in 2017, CMAB Biopharma Inc. operates as a dedicated contract development and manufacturing organization (CDMO) specializing in biologic products. The company's strategic location in Suzhou's BioBAY Park in China positions it as a key partner for biopharmaceutical firms both domestically and globally.
The business model is centered on providing comprehensive, bespoke services that guide clients from the initial DNA concept to the creation of clinical-grade products. This service portfolio includes process development, manufacturing, analytical method development, and formulation for biologic drug substances and drug products. CMAB specifically targets the pre-clinical and early-stage clinical (Phase I/II) manufacturing needs of its clients, adhering to stringent global GMP standards, including those set by the NMPA, FDA, and EMA.
While specific founder details are not publicly available, the leadership team possesses substantial experience from international biopharmaceutical companies, having collectively managed over 100 CDMO projects that led to at least 40 Investigational New Drug (IND) applications. This deep industry expertise underpins the company's service offering.
CMAB Biopharma has demonstrated significant financial traction, securing a $38 million Series A financing round in January 2018, co-led by C-Bridge Capital and BioBAY. This was swiftly followed by a $34 million Series B round in April 2018, led by CD Capital. In a major corporate development, CMAB merged with BioBAY-incubation-platform-company CDMO Gene-Biocon in 2019, further enhancing its service capabilities. Subsequently, in 2021, the company was acquired by the global biopharmaceutical services giant, Porton Pharma Solutions Ltd., marking a new chapter in its growth and integration into a larger, established network.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Suzhou Shi, China
- Employees
- 47
- Open positions
- None listed
- Dealroom signal
- 40.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Apr 2018 | $34M | $136M | C-Bridge Capital · CD Capital | — |
| SERIES A✓Equity / VC | Jan 2018 | — | — | CBC Group | — |
Growth signals
Latest recorded traffic for CMAB BioPharm is 230 monthly website visits, down 25.8% over the last three months. CMAB BioPharm's team grew 2.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
CMAB BioPharm in the Suzhou Shi ecosystem
The CMAB BioPharm office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
CBC Group
CD Capital- CCC-Bridge Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CMAB BioPharm on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CMAB BioPharm’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









